Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 2:42 PM
Ignite Modification Date:
2025-12-26 @ 2:42 PM
NCT ID:
NCT04834206
Eligibility Criteria:
Inclusion Criteria:
* Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III
* Original clinical staged as III-IVa (except T3-4N0) according to the 8th edition American Joint Committee on Cancer staging system
* No evidence of distant metastasis (M0)
* Age between 18-65
* WBC≥4×10\^9/ l, platelet ≥ 100×10\^9/ l and hemoglobin ≥ 90g/l
* With normal liver function test (TBIL、ALT、AST ≤ 2.5×uln)
* With normal renal function test (creatinine ≤ 1.5×uln or ccr ≥ 60ml/min)
* Satisfactory performance status: KARNOFSKY scale (KPS) \> 70
* Patients must give signed informed consent
Exclusion Criteria:
* Treatment with palliative intent
* The primary tumor or lymph node has undergone chemotherapy or surgery (except operations for diagnostic purposes)
* Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer
* History of previous radiotherapy, chemotherapy, or surgery (except diagnostic) to the primary tumor or nodes
* History of previous radiotherapy
* Pregnancy or lactation
* Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, active hepatitis, and mental disturbance.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT04834206
Study Brief:
Protocol Section:
NCT04834206